Biotricity, Inc.
BTCY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.05 | -0.02 | 0.05 |
| FCF Yield | 0.00% | -3.84% | -5.15% | -1.25% |
| EV / EBITDA | 48.06 | 107.78 | -38.14 | -367.47 |
| Quality | ||||
| ROIC | -6.98% | -10.32% | 34.99% | 5.96% |
| Gross Margin | 81.88% | 80.45% | 80.43% | 76.37% |
| Cash Conversion Ratio | -0.60 | 0.56 | 0.21 | 0.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.71% | 10.90% | 12.68% | 13.62% |
| Free Cash Flow Growth | 211.31% | 6.84% | -354.96% | 77.81% |
| Safety | ||||
| Net Debt / EBITDA | 48.06 | 78.58 | -29.29 | -286.74 |
| Interest Coverage | -0.32 | 0.28 | -0.81 | -0.15 |
| Efficiency | ||||
| Inventory Turnover | 0.31 | 0.42 | 0.47 | 0.54 |
| Cash Conversion Cycle | 336.94 | -300.35 | -312.46 | -253.24 |